Jiang Y, Chen C, Liu Y, Wang R, Feng C, Cai L
Front Immunol. 2024; 15:1369376.
PMID: 38638426
PMC: 11024467.
DOI: 10.3389/fimmu.2024.1369376.
Wang Y, Feng R, Cheng G, Huang B, Tian J, Gan Y
Front Med (Lausanne). 2022; 9:887354.
PMID: 35665339
PMC: 9160330.
DOI: 10.3389/fmed.2022.887354.
Li B, Guo Q, Wang Y, Su R, Gao C, Zhao J
Mediators Inflamm. 2020; 2020:6108342.
PMID: 33013198
PMC: 7512106.
DOI: 10.1155/2020/6108342.
Gavriil A, Barisa M, Halliwell E, Anderson J
Cancers (Basel). 2020; 12(8).
PMID: 32824734
PMC: 7463974.
DOI: 10.3390/cancers12082326.
Choudhry H, Helmi N, Abdulaal W, Zeyadi M, Zamzami M, Wu W
Biomed Res Int. 2018; 2018:9056173.
PMID: 29854806
PMC: 5960517.
DOI: 10.1155/2018/9056173.
In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells.
Diaz-Rodriguez Y, Cordeiro P, Belounis A, Herblot S, Duval M
Cancer Immunol Immunother. 2017; 66(10):1307-1320.
PMID: 28555259
PMC: 5626790.
DOI: 10.1007/s00262-017-2022-y.
CCR8FOXp3 T cells as master drivers of immune regulation.
Barsheshet Y, Wildbaum G, Levy E, Vitenshtein A, Akinseye C, Griggs J
Proc Natl Acad Sci U S A. 2017; 114(23):6086-6091.
PMID: 28533380
PMC: 5468670.
DOI: 10.1073/pnas.1621280114.
Inducing and Administering Tregs to Treat Human Disease.
Perdigoto A, Chatenoud L, Bluestone J, Herold K
Front Immunol. 2016; 6:654.
PMID: 26834735
PMC: 4722090.
DOI: 10.3389/fimmu.2015.00654.
TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
Lelaidier M, Diaz-Rodriguez Y, Cordeau M, Cordeiro P, Haddad E, Herblot S
Oncotarget. 2015; 6(30):29440-55.
PMID: 26320191
PMC: 4745738.
DOI: 10.18632/oncotarget.4984.
Tuning IL-2 signaling by ADP-ribosylation of CD25.
Teege S, Hann A, Miksiewicz M, MacMillan C, Rissiek B, Buck F
Sci Rep. 2015; 5:8959.
PMID: 25753532
PMC: 4354014.
DOI: 10.1038/srep08959.
Inhibition of G-protein βγ signaling enhances T cell receptor-stimulated interleukin 2 transcription in CD4+ T helper cells.
Yost E, Hynes T, Hartle C, Ott B, Berlot C
PLoS One. 2015; 10(1):e0116575.
PMID: 25629163
PMC: 4309538.
DOI: 10.1371/journal.pone.0116575.
Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity.
Vaeth M, Bauerlein C, Pusch T, Findeis J, Chopra M, Mottok A
Proc Natl Acad Sci U S A. 2015; 112(4):1125-30.
PMID: 25583478
PMC: 4313840.
DOI: 10.1073/pnas.1409290112.
Clinical significance of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma.
Masuda A, Arai K, Nishihara D, Mizuno T, Yuki H, Kambara T
Biomed Res Int. 2014; 2014:396064.
PMID: 25089268
PMC: 4095742.
DOI: 10.1155/2014/396064.
IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells.
Mizui M, Koga T, Lieberman L, Beltran J, Yoshida N, Johnson M
J Immunol. 2014; 193(5):2168-77.
PMID: 25063876
PMC: 4135016.
DOI: 10.4049/jimmunol.1400977.
Targeting regulatory T cells in cytokine-induced killer cell cultures (Review).
Tao Q, Wang H, Zhai Z
Biomed Rep. 2014; 2(3):317-320.
PMID: 24748966
PMC: 3990197.
DOI: 10.3892/br.2014.234.
Homeostasis and function of regulatory T cells (Tregs) in vivo: lessons from TCR-transgenic Tregs.
Attridge K, Walker L
Immunol Rev. 2014; 259(1):23-39.
PMID: 24712457
PMC: 4237543.
DOI: 10.1111/imr.12165.
Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.
Skrombolas D, Frelinger J
Expert Rev Clin Immunol. 2014; 10(2):207-17.
PMID: 24410537
PMC: 4072333.
DOI: 10.1586/1744666X.2014.875856.
Regulatory T-cell therapy in transplantation: moving to the clinic.
Tang Q, Bluestone J
Cold Spring Harb Perspect Med. 2013; 3(11).
PMID: 24186492
PMC: 3808774.
DOI: 10.1101/cshperspect.a015552.
The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus.
Golding A, Hasni S, Illei G, Shevach E
Arthritis Rheum. 2013; 65(11):2898-906.
PMID: 23925905
PMC: 3891045.
DOI: 10.1002/art.38119.
Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection.
Jenabian M, Seddiki N, Yatim A, Carriere M, Hulin A, Younas M
PLoS Pathog. 2013; 9(4):e1003319.
PMID: 23658513
PMC: 3635970.
DOI: 10.1371/journal.ppat.1003319.
